GlassScriptPhysician profile
Dushyant Singh
NPI 1598780660
$986.37
in general payments reported to CMS, 2019-2025
17 companies · $274 in 2025
The $274 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $280 · 2020: $76.47 · 2021: $12.13 · 2024: $343 · 2025: $274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $617.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $189.11 | 2019-2025 | |
| Abbvie INC. | $155.17 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $146.06 | 2025 | Monoferric |
| Covidien LP | $130.26 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.62 | 2020-2024 | Entyvio |
| Qol Medical, LLC | $49.47 | 2024-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $39.55 | 2024 | Stelara |
| Lilly USA, LLC | $30.77 | 2024 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $30.60 | 2024 | Dupixent |
| Merck Sharp & Dohme LLC | $30.41 | 2019-2024 | Dificid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.74 | 2024 | Xifaxan |
| Allergan, INC. | $19.56 | 2019 | |
| Gilead Sciences, INC. | $18.78 | 2024 | |
| Genzyme Corporation | $17.93 | 2024 | |
| Ardelyx, INC. | $14.35 | 2024 | Ibsrela |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $13.38 | 2024 | |
| Ferring Pharmaceuticals INC. | $11.61 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dushyant Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.